Navitas Life Sciences

Successfully managing ongoing and new Oncology studies throughout the COVID-19 pandemic

The COVID-19 pandemic has disrupted clinical trials across the globe. In our latest Case Study, we explore just how we have maintained business continuity, not only enabling the continuation of existing Oncology studies, but also carrying out new studies.

With immunocompromised patients at an increased risk of contracting COVID-19, this has not been without its challenges, but with the correct infrastructure, logistics, and digitalization we have successfully managed these Oncology studies throughout the pandemic to, hopefully, bring much needed treatments to those that need them.

Please complete the form to download the Case Study and learn more.

Please complete form to download PDF
First Name
Last Name
Business Email
Job Title
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy | EU-US & Swiss-US Privacy Shield Policy

© 2021 Navitas Life Sciences | Privacy Policy